London midday: UK stocks keep grinding towards year's highs
3rd Oct 2025 11:15
(Sharecast News) - Stocks are moving higher still shortly before midday with investor sentiment buoyed by fresh bullish news around the artificial intelligence space, even as investors keep a wary eye on the ongoing budget standoff in Washington D.C..
Read moreTrump's MFN deal with Pfizer could be bellwether for pharma sector, says JPM
1st Oct 2025 09:26
(Sharecast News) - US President Donald Trump's 'Most Favoured Nation' deal with Pfizer could be a bellwether for the pharmaceutical sector and reassure investors over a broadly manageable impact, JPMorgan said in a research note
Read moreAstraZeneca to list in New York, retain London
29th Sep 2025 09:24
(Sharecast News) - Anglo-Swedish drugs giant AstraZeneca is to list directly on the New York Stock Exchange, it was announced on Monday.
Read moreTrump to impose tariffs of 100% on branded drug imports
26th Sep 2025 07:53
(Sharecast News) - Donald Trump is to impose tariffs of 100% on imports of pharmaceutical goods, it emerged on Friday, the latest salvo in the US president's global trade war.
Read moreEU approves AstraZeneca's Tezspire to treat nasal conditions
22nd Sep 2025 07:06
(Sharecast News) - AstraZeneca and Amgen on Monday said their Tezspire drug has been recommended for approval in the European Union for the treatment of adult patients with chronic rhinosinusitis with nasal polyps.
Read moreLondon close: Stocks mixed ahead of central bank decisions
15th Sep 2025 17:51
(Sharecast News) - London stocks ended mixed on Monday as investors adopted a cautious stance ahead of a series of major central bank policy decisions due later this week.
Read moreAstraZeneca to pause £200m Cambridge investment, shares slump
15th Sep 2025 08:58
(Sharecast News) - AstraZeneca slumped on Monday after saying it was pausing plans to invest £200m at its Cambridge research site.
Read moreLondon close: Stocks fall on Trump's latest tariffs, US jobs data
1st Aug 2025 17:37
(Sharecast News) - London stocks ended the week lower on Friday as investors reacted to a fresh wave of US tariffs and disappointing economic data from the United States.
Read moreLondon close: Stocks mixed on corporate updates, trade developments
29th Jul 2025 16:28
(Sharecast News) - London stocks ended Tuesday on a mixed note as a wave of corporate results kept investors busy and market participants continued to assess the implications of the recent US-EU trade deal.
Read moreAstrazeneca H1 gross profits up 10pc as 'strong growth momentum' continues
29th Jul 2025 07:09
(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline delivery" in the year-to-date.
Read moreLondon close: Stocks reverse gains to finish lower
28th Jul 2025 17:16
(Sharecast News) - London stocks ended lower on Monday, erasing earlier gains as investors reassessed the weekend's trade agreement between the United States and the European Union.
Read moreAstraZeneca reports positive results from autoimmune treatment trial
24th Jul 2025 08:27
(Sharecast News) - AstraZeneca announced on Thursday that its investigational treatment 'gefurulimab' achieved statistically significant and clinically meaningful results in a phase three trial for generalised myasthenia gravis (gMG), a rare autoimmune neuromuscular disorder.
Read moreAstraZeneca to invest $50bn in US manufacturing and R&D
22nd Jul 2025 07:06
(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that it plans to invest $50.0bn in the US for medicines manufacturing and R&D by 2030.
Read moreLondon close: Stocks fall after rise in UK consumer inflation
16th Jul 2025 17:49
(Sharecast News) - London equities slipped on Wednesday as stronger-than-expected UK inflation data offset a decline in US producer inflation, prompting investor caution over the interest rate outlook.
Read moreAstraZeneca drug fails to meet main goal in late-stage amyloidosis trial
16th Jul 2025 07:31
(Sharecast News) - An investigational AstraZeneca treatment for amyloidosis has failed to show a statistical significance in late-stage trials, the blue chip pharmaceutical group said on Wednesday.
Read more